Cutter Capital Management
Latest statistics and disclosures from Cutter Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMY, GILD, TEVA, REGN, BMRN, and represent 34.99% of Cutter Capital Management's stock portfolio.
- Added to shares of these 10 stocks: GILD (+$19M), BMY (+$17M), REGN (+$16M), IONS (+$13M), SRPT (+$12M), BIIB (+$11M), Avadel Pharmaceuticals (+$9.2M), LLY (+$8.6M), AGIO (+$8.4M), ACLX (+$7.4M).
- Started 12 new stock positions in GILD, BIIB, SRPT, IONS, Avadel Pharmaceuticals, LLY, Kyverna Therapeutics, REGN, AGIO, ACLX. LEGN, PLRX.
- Reduced shares in these 10 stocks: AMGN (-$17M), , , ROIV (-$11M), PFE (-$7.6M), APLS (-$6.5M), IOVA (-$5.5M), , INSM (-$5.1M), BBIO.
- Sold out of its positions in AMGN, FOLD, APLS, RCUS, BBIO, IOVA, MRK, PFE, PBH, ROIV.
- Cutter Capital Management was a net buyer of stock by $55M.
- Cutter Capital Management has $259M in assets under management (AUM), dropping by 23.99%.
- Central Index Key (CIK): 0001983313
Tip: Access up to 7 years of quarterly data
Positions held by Cutter Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cutter Capital Management
Cutter Capital Management holds 25 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 9.3 | $24M | +219% | 447k | 54.23 |
|
| Gilead Sciences (GILD) | 7.5 | $19M | NEW | 265k | 73.25 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 6.2 | $16M | +6% | 1.1M | 14.11 |
|
| Regeneron Pharmaceuticals (REGN) | 6.1 | $16M | NEW | 16k | 962.49 |
|
| BioMarin Pharmaceutical (BMRN) | 5.9 | $15M | +34% | 175k | 87.34 |
|
| Ionis Pharmaceuticals (IONS) | 4.8 | $13M | NEW | 289k | 43.35 |
|
| Royalty Pharma Shs Class A (RPRX) | 4.8 | $13M | +11% | 412k | 30.37 |
|
| Sarepta Therapeutics (SRPT) | 4.7 | $12M | NEW | 94k | 129.46 |
|
| ACADIA Pharmaceuticals (ACAD) | 4.7 | $12M | +98% | 658k | 18.49 |
|
| Biogen Idec (BIIB) | 4.3 | $11M | NEW | 52k | 215.63 |
|
| BioCryst Pharmaceuticals (BCRX) | 4.1 | $11M | +38% | 2.1M | 5.08 |
|
| Halozyme Therapeutics (HALO) | 4.0 | $10M | +6% | 255k | 40.68 |
|
| Perrigo SHS (PRGO) | 4.0 | $10M | +23% | 322k | 32.19 |
|
| Exelixis (EXEL) | 3.6 | $9.5M | -13% | 399k | 23.73 |
|
| Avadel Pharmaceuticals SHS | 3.5 | $9.2M | NEW | 542k | 16.89 |
|
| Eli Lilly & Co. (LLY) | 3.3 | $8.6M | NEW | 11k | 777.96 |
|
| Agios Pharmaceuticals (AGIO) | 3.3 | $8.4M | NEW | 289k | 29.24 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 3.2 | $8.2M | +11% | 120k | 68.16 |
|
| Arcellx Common Stock (ACLX) | 2.9 | $7.4M | NEW | 107k | 69.55 |
|
| Insmed Com Par $.01 (INSM) | 2.4 | $6.2M | -45% | 227k | 27.13 |
|
| Miragen Therapeutics (VRDN) | 1.9 | $4.9M | -9% | 279k | 17.51 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.7 | $4.5M | NEW | 80k | 56.09 |
|
| Kyverna Therapeutics | 1.6 | $4.1M | NEW | 167k | 24.84 |
|
| Pliant Therapeutics (PLRX) | 1.1 | $2.9M | NEW | 194k | 14.90 |
|
| Cabaletta Bio (CABA) | 1.0 | $2.7M | -31% | 158k | 17.06 |
|
Past Filings by Cutter Capital Management
SEC 13F filings are viewable for Cutter Capital Management going back to 2023
- Cutter Capital Management 2024 Q1 filed May 15, 2024
- Cutter Capital Management 2023 Q4 filed Feb. 14, 2024